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Long-term trends of HIV type 1 drug resistance prevalence
among antiretroviral treatment-experienced patients in
Switzerland
Abstract
BACKGROUND:Accurate quantification of the prevalence of human immunodeficiency virus type 1
(HIV-1) drug resistance in patients who are receiving antiretroviral therapy (ART) is difficult, and
results from previous studies vary. We attempted to assess the prevalence and dynamics of resistance in
a highly representative patient cohort from Switzerland. METHODS:On the basis of genotypic
resistance test results and clinical data, we grouped patients according to their risk of harboring resistant
viruses. Estimates of resistance prevalence were calculated on the basis of either the proportion of
individuals with a virologic failure or confirmed drug resistance (lower estimate) or the
frequency-weighted average of risk group-specific probabilities for the presence of drug resistance
mutations (upper estimate). RESULTS:Lower and upper estimates of drug resistance prevalence in 8064
ART-exposed patients were 50% and 57% in 1999 and 37% and 45% in 2007, respectively. This
decrease was driven by 2 mechanisms: loss to follow-up or death of high-risk patients exposed to mono-
or dual-nucleoside reverse-transcriptase inhibitor therapy (lower estimates range from 72% to 75%) and
continued enrollment of low-risk patients who were taking combination ART containing boosted
protease inhibitors or nonnucleoside reverse-transcriptase inhibitors as first-line therapy (lower
estimates range from 7% to 12%). A subset of 4184 participants (52%) had >or= 1 study visit per year
during 2002-2007. In this subset, lower and upper estimates increased from 45% to 49% and from 52%
to 55%, respectively. Yearly increases in prevalence were becoming smaller in later years.
CONCLUSIONS:Contrary to earlier predictions, in situations of free access to drugs, close monitoring,
and rapid introduction of new potent therapies, the emergence of drug-resistant viruses can be
minimized at the population level. Moreover, this study demonstrates the necessity of interpreting time
trends in the context of evolving cohort populations.
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Background. Accurate quantification of the prevalence of human immunodeficiency virus type 1 (HIV-1) drug
resistance in patients who are receiving antiretroviral therapy (ART) is difficult, and results from previous studies
vary. We attempted to assess the prevalence and dynamics of resistance in a highly representative patient cohort
from Switzerland.
Methods. On the basis of genotypic resistance test results and clinical data, we grouped patients according to
their risk of harboring resistant viruses. Estimates of resistance prevalence were calculated on the basis of either
the proportion of individuals with a virologic failure or confirmed drug resistance (lower estimate) or the frequency-
weighted average of risk group–specific probabilities for the presence of drug resistance mutations (upper estimate).
Results. Lower and upper estimates of drug resistance prevalence in 8064 ART-exposed patients were 50%
and 57% in 1999 and 37% and 45% in 2007, respectively. This decrease was driven by 2 mechanisms: loss to
follow-up or death of high-risk patients exposed to mono– or dual–nucleoside reverse-transcriptase inhibitor
therapy (lower estimates range from 72% to 75%) and continued enrollment of low-risk patients who were taking
combination ART containing boosted protease inhibitors or nonnucleoside reverse-transcriptase inhibitors as first-
line therapy (lower estimates range from 7% to 12%). A subset of 4184 participants (52%) had 1 study visit
per year during 2002–2007. In this subset, lower and upper estimates increased from 45% to 49% and from 52%
to 55%, respectively. Yearly increases in prevalence were becoming smaller in later years.
Conclusions. Contrary to earlier predictions, in situations of free access to drugs, close monitoring, and rapid
introduction of new potent therapies, the emergence of drug-resistant viruses can be minimized at the population
level. Moreover, this study demonstrates the necessity of interpreting time trends in the context of evolving cohort
populations.
During the past decade, combination antiretroviral
therapy (cART) has markedly decreased morbidity and
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mortality among HIV-1–infected patients in the West-
ern world [1, 2]. However, therapy success is compro-
mised if the virus becomes antiretroviral resistant [3–
6]. Drug resistance mutations emerge rapidly under
nonsuppressive antiretroviral treatments because of the
fast replication of HIV-1 [7–9] and the error-prone
reverse transcription process [10] with its high muta-
tion rate. There is a general concern that the problem
Presented in part: 15th Conference on Retroviruses and Opportunistic Infections,
Boston, Massachusetts, 3–6 February 2008 (poster 896).
a Members of the Swiss HIV Cohort Study group are listed at the end of the
text.
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of drug resistance against cART will inevitably worsen with
prolonged duration of antiretroviral therapy (ART) and even-
tually leave many HIV-1–infected patients without treatment
options [11, 12]. Our overall aim was to reexamine those pre-
dictions in light of the recent advances in HIV medicine, such
as the registration of new antiretroviral compounds. We as-
sessed drug resistance prevalence over time in ART-experienced
patients of the Swiss HIV Cohort Study with genotypic infor-
mation available. Moreover, we sought to extend those esti-
mates to the study population without available drug resistance
tests by estimating their risk for the presence of drug resistance
mutations on the basis of treatment history and measurements
of HIV RNA concentration.
METHODS
Study population. The Swiss HIV Cohort Study is a nation-
wide cohort study with continuous enrollment and semiannual
study visits [2]. The Swiss HIV Cohort Study has been approved
by the ethics committees of all participating institutions, and
written informed consent is obtained from participants. The
Swiss HIV Cohort Study drug resistance database contains the
results of all genotypic tests performed by the 4 laboratories
engaged in resistance testing in Switzerland stored in a central
database (SmartGene; Integrated Database Network System
version 3.5.0) [13]. Drug resistance was defined as the presence
of 1 major mutation of the fall 2007 International AIDS
Society–USA drug mutation list [14]. Mutations that confer
resistance to fusion inhibitors were not considered. In addition,
the following mutations listed as specific for etravirine were
excluded, because several of them may be polymorphic, and
inclusion of them would yield exaggerated prevalence estimates
(A. U. Scherrer, V.v.W., H.F.G.; unpublished data): V90I, A98G,
K101E/H/P, V106I, E138A, V179D/F/T, Y181V, and M230L.
This study included ART-experienced patients who attended
at least 1 visit after 1 January 1999. For patients who initiated
ART before enrollment in the Swiss HIV Cohort Study, inclu-
sion was restricted to individuals with a sufficiently documented
treatment history to assess their probability for the presence of
drug resistance mutations. In particular, for each therapy
started before Swiss HIV Cohort Study enrollment, 1 on-
treatment HIV RNA measurement at least 180 days after ther-
apy start was required for inclusion. To assess the impact of
continuous enrollments and dropouts of participants on prev-
alence estimates, we repeated all analyses on a subset of indi-
viduals who had been seen in each year between 2002 (1 year
after the introduction of lopinavir in Switzerland) and 2007.
This subgroup was termed the “closed cohort,” in contrast to
the “open cohort,” which included all patients seen since 1999.
Statistical analysis. To estimate the prevalence of drug re-
sistance, we classified all cohort patients into 2 prespecified
categories. The first group consisted of patients considered at
high risk for the emergence of drug-resistant HIV, either be-
cause they had experienced virologic failure while receiving
therapy or because they had been exposed to single or dual
nucleoside reverse-transcriptase inhibitor (NRTI) therapy (vi-
rologic failure group). We defined virologic failure as 2 con-
secutive plasma HIV RNA levels 1500 copies/mL after 1180
days of ART or a single HIV RNA level 1500 copies/mL fol-
lowed by discontinuation or modification of treatment. The
second group included individuals who were at low risk for
the emergence of resistance because they were either not un-
dergoing treatment or had remained virologically suppressed
while receiving therapy, defined as at least 2 consecutive viral
loads of !50 copies/mL while receiving the same treatment in
a given year (low-risk group), whereby undetectable HIV RNA
levels were coded as the detection limit minus 1 copy. All re-
maining patients were classified as having an unknown status
(the unknown group). For an estimate of prevalence of resis-
tance within these groups, genotypic tests were classified ac-
cording to the patients’ group memberships at time of sam-
pling, and the proportion of tests with at least 1 major
International AIDS Society–USA resistance mutation was cal-
culated for each group. Tests from the low-risk and unknown
groups were performed while the patients were not undergoing
treatment, during the initial viral load decay while undergoing
treatment, or during intermittent viremia (viral load, 500
copies/mL) while receiving therapy. It was assumed that, once
detected, transmitted or acquired mutations would persist.
We derived lower-bound and upper-bound estimates of drug
resistance prevalence. The upper bound was defined as the
mean of group-specific probabilities of the presence of drug
resistance mutations for the virologic failure, low-risk, and un-
known groups, weighted by the respective group size. This ap-
proach assumed that patients with a genotypic test from the
low-risk and unknown groups (i.e., those without indication
for testing according to guidelines [15]) were representative of
the remaining individuals from their respective groups. The
lower bound estimate was calculated as the proportion of pa-
tients either belonging to the virologic failure group or who
were members of the low-risk and unknown groups with test
results positive for drug-resistant HIV. Linear time trends in
prevalence estimates were assessed using a generalized linear
model [16]. Trend analyses were stratified according to the first
ART received: patients who had started with standard cART
containing at least 3 drugs from 2 classes [17] and those who
had initially received treatments not qualifying as cART, which
were subsumed under the historic ART group. Most (89%) of
these latter patients were treated with 1 or 2 NRTIs as first
therapy; 4% had received 3 NRTIs that contained abacavir. The
remaining patients had received non-NRTIs (NNRTIs) or pro-
tease inhibitors (PIs) combined with 1 NRTI. The cART group
was further divided to account for the differences in potency
Table 1. Description of characteristics for ART-experienced participants.
Characteristics
Open cohort
(n p 8064)
Closed cohort
(n p 4184)
Characteristics at ART initiation
Female sex 2530 (31.4) 1296 (31.0)
Age at first visit, median years (IQR) 44 (38–50) 46 (42–52)
Ethnicity
White 6400 (79.4) 3564 (85.2)
Asian 251 (3.1) 123 (2.9)
Black 958 (11.9) 415 (9.9)
Hispanic 164 (2.0) 67 (1.6)
Unknown 291 (3.6) 15 (0.4)
Mode of HIV acquisition
Heterosexual sex 3064 (38.0) 1545 (36.9)
Male-male sex 2783 (34.5) 1568 (37.5)
Injection drug use 1902 (23.6) 905 (21.6)
Other 315 (3.9) 166 (4.0)
Median year of ART initiation (IQR) 1998 (1996–2002) 1997 (1996–1999)
Type of initial ART
Historic ART 3071 (38.1) 2012 (48.1)
cART 2233 (27.7) 1485 (35.5)
Potent cART 2760 (34.2) 687 (16.4)
CDC stage C event 1549 (19.2) 791 (18.9)
CD4 cell count, cells/mm3
No. of available measurements 6978 3513
Median (IQR) 222 (113–341) 230 (108–360)
HIV RNA level, log10 copies/mL
No. of available measurements 5068 2258
Median (IQR) 4.85 (4.25–5.33) 4.81 (4.20–5.26)
Characteristic at last follow-up visit
Last available CD4 cell count, median cells/mm3(IQR) 454 (296–643) 507 (360–706)
Risk status for presence of drug-resistance mutations
Any history of virologic failure 2708 (33.6) 1776 (42.4)
Any exposure to mono- or dual-drug NRTI therapy or history of virologic failure 3769 (46.7) 2478 (59.2)
Consistent virologic suppression while receiving ART 3104 (38.5) 1168 (27.9)
Unknown risk status 1191 (14.8) 538 (12.9)
Any genotypic resistance testing after ART initiation 3278 (40.6) 2200 (52.6)
M184V/I mutation 1357 (16.8) 955 (22.8)
Any NNRTI mutation 715 (8.9) 483 (11.5)
Any NRTI mutation (other than the M184V/I mutation) 1629 (20.2) 1109 (26.5)
Any PI mutation 1001 (12.4) 684 (16.3)
1 Resistance mutation 2280 (28.3) 1526 (36.5)
Resistance to 2 drug classes 1186 (14.7) 826 (19.7)
Resistance to 3 drug classes 312 (3.9) 224 (5.4)
Loss to follow-up 1298 (16.1) NA
Death
All causes 752 (9.3) NA
AIDS related 218 (2.7) NA
NOTE. Data are no. (%) of patients, unless otherwise indicated. The open cohort included all study participants seen at least once in the
Swiss HIV Cohort Study since 1999. The closed cohort was defined as the subset of individuals with at least 1 study visit per year from 2002
through 2007. ART, antiretroviral therapy; cART, combination antiretroviral therapy; CDC, Centers for Disease Control and Prevention; IQR, inter-
quartile range; NA, not applicable; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, nonnucleoside reverse-transcriptase inhibitor; PI, pro-
tease inhibitor.
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Figure 1. Evolution of antiretroviral treatment (ART)–experienced population from 1999 through 2007 (A) and of the subset of participants with at
least 1 study visit per year from 2002 through 2007 (B). IAS-USA, International AIDS Society-USA; NRTI, nucleoside reverse-transcriptase inhibitor.
Figure 2. Estimate of the prevalence of drug resistance mutations.
Antiretroviral treatment (ART)–experienced patients were classified ac-
cording to their risk of harboring drug-resistant HIV: high probability due
to exposure to mono– or dual–nucleoside reverse-transcriptase inhibitor
therapy or because of virologic failures (dark blue shaded area plus
adjacent violet area below), low risk for resistance emergence because
always receiving or not receiving virologically suppressive therapies (light
blue area plus adjacent violet area below), and patients with unknown
status (blue area with intermediate shading intensity plus adjacent violet
area below). Violet shaded areas indicate the subset of participants from
a respective group with confirmed presence of drug resistance mutations.
Broken lines, upper and lower prevalence estimates.
between unboosted PIs (cART group) and newer treatments,
including either an NNRTI or a ritonavir-boosted PI (potent
cART group) [13, 18].
Sensitivity analyses were conducted by restricting estimation
of prevalence to genotypic tests performed on treatment and
by considering patients lost to follow-up as having experienced
virologic failure. Conclusions were not altered by these analyses.
RESULTS
Patient demographic characteristics of the open and closed
cohorts. From 1 January 1999 through 31 December 2007, a
total of 8569 patients exposed to ART were observed in the
Swiss HIV Cohort Study. Of these, 505 (5.9%) were excluded
from the analysis because of insufficient information to assess
their probability of harboring resistant viruses, leaving 8064
individuals, whom we defined as our open cohort. For the
closed cohort, we only included the subset of 4184 patients
active from 2002 through 2007 (table 1).
Figure 1A summarizes the evolution of the open cohort. The
size of the ART-experienced population increased, whereas the
population of patients with exposure to mono- or dual-NRTI
treatment or with virologic failures diminished over time. The
proportion of patients who had undergone genotypic resistance
testing after initiation of ART also increased steadily, although
the slowed growth from 2004 onward suggests that, in recent
years, the numbers of patients with an indication for testing
and tests performed have reached a steady state: fewer patients
experienced virologic failure, and those who had experienced
virologic failure were more likely to have undergone resistance
testing. In fact, among patients who experienced virologic fail-
ure while receiving ART, 80% had undergone at least 1 ge-
notypic resistance test by 2007, up from 41% in 1999 (data not
shown).
Estimation of drug resistance prevalence. To determine the
prevalence of resistance, we classified ART-exposed patients by
their probability of harboring resistant viruses based on their
treatment history. With use of genotypic information from all
participants (open cohort), we estimated the probability of the
presence of International AIDS Society–USA mutations at
77.1% (95% CI, 75.4–78.7; number of tests, 2516) for patients
with exposure to mono- or dual-NRTI therapy or virologic
failures (virologic failure group), 15.7% (95% CI, 12.4%–
19.4%; number of tests, 440) for patients who were at low risk
for the emergence of resistance because they were not under-
going treatment or had always remained virologically sup-
pressed while receiving therapy (low-risk group), and 34.8%
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Figure 3. Prevalence and time trends of drug resistance by type of initial antiretroviral therapy (ART). A, Upper and lower prevalence estimates
for all participants seen at least once since 1999 (open cohort) and the subset who were seen every year between 2002 and 2007 (closed cohort;
indicated by gray bar on the x axis). B, Yearly change in prevalence derived from fitting a generalized linear regression model through the prevalence
curves displayed in A and figure 2. Black symbols, estimates from the open cohort; gray symbols, estimates from the closed cohort. Estimates shown
in the L columns show lower estimates, and those in the U columns show upper estimates. cART, combination antiretroviral therapy.
Figure 4. Evolution of the antiretroviral therapy (ART)–experienced Swiss HIV Cohort Study population. The graphs in A, B, and C display changes
over time in the size of the ART-exposed population, the patient group with exposure to mono or dual nucleoside reverse transcriptase inhibitor (NRTI)
therapy or at least 1 virologic failure event, and patients with drug resistance confirmed by genotypic testing, respectively. Top row, bar charts showing
the yearly net change of the population; gray shaded bars, the magnitude of losses to follow-up and deaths; white bars, the number of patients
newly joining a subpopulation, by starting ART (A), experiencing the first virologic failure (B), or testing positive for drug resistance mutations for the
first time (C). The bars are arranged such that the numbers represented by the gray bar and the fraction of the white bar below the zero line cancel
each other out. Thus, for all the panels, the net change per year is indicated by the upper edge of the white bars. A bar protruding above 0 indicates
a net increase of a subpopulation in a given year, whereas bars ending below the zero line stand for a decrease. Bottom row, change in frequency
of ART-experienced patients (A), patients with a virologic failure or exposure to mono– or dual–nucleoside reverse-transcriptase (NRTI) therapy (B),
and patients harboring drug-resistant HIV, confirmed by genotypic resistance testing (C); shaded areas, the proportion of patients who initiated therapy
with historic ART (dark shade), combination antiretroviral therapy (cART) containing unboosted protease inhibitors (intermediate shade intensity), or
cART with boosted protease inhibitors or nonnucleoside reverse-transcriptase inhibitors (light shade). Note that black lines and symbols correspond
to those in figure 1. IAS-USA, International AIDS Society-USA.
(95% CI, 29.6%–40.3%; number of tests, 322) for patients in
the unknown group.
In the open cohort, the lower estimate of resistance preva-
lence for 2007, under the assumption that probabilities for
resistance mutations in the low-risk and unknown groups were
0 unless confirmed by resistance testing (figure 2A), was 37.4%.
For the upper estimate, resistance prevalence derived from
tested patients in the low-risk and unknown groups was ex-
trapolated to all untested individuals in these groups and
yielded a prevalence of 45.1% for 2007. Those numbers were
notably lower than estimates obtained for 1999 (49.7% [lower]
and 56.6% [upper]). In the closed cohort, lower and upper
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Table 2. Comparison of the actively observed study population, patients who were lost to follow-up, and patients
who had died.
Characteristic
Patients who
were still being
observed in
2007a
(n p 6014)
Patients lost to
follow-up
(n p 1298)
Patients who
died
(n p 752)
Adjusted OR (95% CI)b
PcLoss to follow-up Death
Female sex 1882 (31.3) 449 (34.6) 198 (26.3) 0.66 (0.56–0.77) 0.63 (0.51–0.77) !.001
Age at ART initiation,
median years (IQR) 45 (40–51) 40 (35–45) 43 (38–51) NAd NAd
Mode of HIV acquisition !.001
Heterosexual sex 2380 (39.6) 499 (38.4) 185 (24.6) 1.40 (1.15–1.71) 1.23 (0.96–1.57)
Male-male sex 2275 (37.8) 306 (23.6) 202 (26.9) Referent Referent
Injection drug use 1110 (18.5) 454 (35.0) 338 (44.9) 2.04 (1.55–2.69) 2.29 (1.65–3.16)
Other 249 (4.1) 39 (3.0) 27 (3.6) 0.82 (0.54–1.22) 1.17 (0.74–1.86)
Region of origin !.001
Northwestern Europe 4321 (71.8) 851 (65.6) 643 (85.5) Referent Referent
Sub-Saharan Africa 654 (10.9) 182 (14.0) 19 (2.5) 1.26 (0.99–1.60) 0.29 (0.17–0.48)
Southern Europe 469 (7.8) 136 (10.5) 55 (7.3) 1.23 (0.98–1.55) 0.65 (0.47–0.88)
Latin America 190 (3.2) 49 (3.8) 8 (1.1) 1.27 (0.88–1.83) 0.41 (0.20–0.85)
South and East Asia 180 (3.0) 23 (1.8) 4 (0.5) 0.59 (0.36–0.96) 0.20 (0.07–0.55)
Eastern Europe 106 (1.8) 25 (1.9) 12 (1.6) 1.33 (0.80–2.19) 1.12 (0.59–2.12)
Other 94 (1.6) 32 (2.5) 11 (1.5) 1.64 (1.04–2.59) 0.85 (0.44–1.65)
Type of initial therapy .135
Historic ART 2091 (34.8) 552 (42.6) 428 (56.9) Referent Referent
cART 1561 (26.0) 468 (36.1) 204 (27.1) 0.99 (0.81–1.22) 0.74 (0.57–0.97)
Potent cART 2362 (39.3) 278 (21.4) 120 (16.0) 0.90 (0.68–1.19) 0.64 (0.44–0.94)
Median year of ART ini-
tiation (IQR) 1999 (1996–2004) 1997 (1996–2000) 1996 (1995–1999) NAd NAd
CD4 cell count at ART
initiation, cells/mm3
No. of available
measurements 5012 978 644 … …
Median (IQR) 220 (112–335) 227 (118–355) 180 (82.5–300) NAe… NAe
Any history of hepatitis
C virus coinfection 1404 (23.3) 514 (39.6) 380 (50.5) 1.30 (1.03–1.64) 1.59 (1.20–2.11) .002
Any history of a CDC
stage C event 1607 (26.7) 334 (25.8) 397 (52.8) 1.00 (0.85–1.17) 2.75 (2.30–3.28) !.001
Any history of virologic
failure 1838 (30.6) 490 (37.8) 380 (50.5) 1.24 (1.04–1.47) 1.31 (1.06–1.62) .007
Any history of genotypic
resistance testing 2406 (40.0) 486 (37.4) 386 (51.3) 0.56 (0.47–0.68) 0.71 (0.56–0.90) !.001
Any history of detected
drug resistance
mutations 1665 (27.7) 325 (25.0) 290 (38.6) 0.88 (0.71–1.09) 1.02 (0.79–1.31) .468
NOTE. Data are no. (%) of patients, unless otherwise indicated. Patients were considered lost to follow-up if they did not respond to
written invitations for 114 months or if they wished to discontinue study participation. Only deaths occurring up to 180 days after study
participation discontinuation were considered. ART, antiretroviral therapy; cART, combination antiretroviral therapy; CDC, Centers for Disease
Control and Prevention; IQR, interquartile range; NA, not applicable.
a Reference outcome.
b The ORs are from multivariable polytomous logistic regression with the category “still alive in 2007” as base outcome. Adjustments were
made for all covariables listed in the table.
c P values were obtained from likelihood ratio tests and indicate whether the inclusion of a variable significantly improved model fit.
d Age and year of ART initiation were included as confounders and modeled as cubic splines with knots at the 25th, 50th, and 75th centiles.
e The CD4 cell count at ART initiation was included as a confounder and modeled as a categorical variable with 4 groups on the basis of
centiles and an additional category for missing data.
estimates were continuously increasing from 45.0% to 49.4%
(lower) and from 51.7% to 54.6% (upper) from 2002 through
2007 (figure 2B); this was to be expected, however, because of
our approach to carry forward detected resistance mutations.
Different trends also emerged when analyses were repeated with
stratifications for type of initial ART (figure 3). With the ex-
ception of the historic ART group, in whom resistance mu-
tations are already frequent, prevalence of resistance generally
appeared to be increasing over time. Change rates derived from
lower estimates were 1.5 (open cohort) and 1.2 (closed cohort)
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percentage points per year for the cART group and 0.6 (open)
and 1.6 (closed) percentage points for the potent cART group,
respectively (figure 3B). However, increases, especially those for
lower estimates, tended to be much steeper during the first few
years of our observational period (figure 3A), and thus, linear
trends must be interpreted cautiously.
Shifts in study population as explanation for time trends.
To explore reasons for the differences in time trends between
the open and closed cohorts, we analyzed shifts in the distri-
bution of patients exposed to different first-line treatments (his-
toric ART group, cART group, and potent cART group), sym-
bolic for different propensities for the presence of drug-resistant
HIV. According to figure 4A, the number of patients who had
initiated therapy with potent combinations increased steadily
(2441 patients [39.1%]) and exceeded the number of patients
from the historic ART category (2181 patients [35.0%]) by
2007. Figure 4B indicates a decrease in the number of patients
with virologic failure or exposure to mono- or dual-NRTI ther-
apy and who are, thus, at high risk for the emergence of drug
resistance mutations. This decrease was caused by a continuous
loss of patients exposed to historic ART as initial treatment
from the study population, which was confirmed with a mul-
tinomial logistic regression model to study factors associated
with losses to follow-up or deaths (table 2). Of further note,
the availability of a genotypic drug resistance test was associated
with a smaller probability for being lost to follow-up or death,
most likely because this may also be an indicator for good
patient compliance and regular attendance of physician ap-
pointments. After controlling for resistance testing, the presence
of International AIDS Society–USA drug resistance mutations
was not associated with a higher probability of death, although
crude percentages would suggest so.
DISCUSSION
On the basis of data from a highly representative cohort for
the HIV-1 epidemic in Switzerland, we estimate that drug re-
sistance prevalence in ART-exposed patients decreased from
1999 through 2007 in the population of HIV-infected patients.
Our upper estimate was 57% in 1999 and 45% in 2007, whereas
our low estimate was 50% in 1999 and 37% in 2007. Such
apparent time trends must be interpreted cautiously and in the
context of the changing composition of the HIV-1–infected
population over time. The proportion of patients exposed to
historic ART, such as single-class NRTI therapy, generally re-
garded as a population with a high prevalence of drug-resistance
mutations, decreased markedly. On the other hand, the patient
group treated with combination therapy from the start and
therefore at a much lower risk for the emergence of drug re-
sistance grew over time, thus leading to a dilution effect. In
contrast, when analyzing trends within a fixed subset of pa-
tients, drug resistance prevalence was increasing steadily as ex-
pected, yet at progressively smaller rates. Thus, our analysis
demonstrates the potential biases and pitfalls of time trends
derived from cohorts with continuous enrollment, if shifts in
population composition are not considered.
Compared with other surveys, estimates of drug resistance
prevalence from this study were considerably lower and most
likely reflect the different methods. Most studies relied on anal-
yses of drug resistance databases, which yielded probabilities
for the presence of at least 1 drug resistance mutation of 76%–
90% [19–24]. However, patients who had undergone drug re-
sistance tests are not representative of the entire ART-exposed
population, and studies of such patients tend to be biased to-
ward patients who had experienced problems while undergoing
therapy. For example, in the Swiss HIV Cohort Study in 2007,
44% of ART-exposed patients had never experienced a virologic
failure and thus had no indication for drug resistance testing.
Results from the present study are in line with a survey from
the United States that relied on cross-sectional sampling, which
estimated the prevalence of resistance mutations at 76% among
viremic patients with an HIV RNA level 1500 copies/mL [25].
Since viremic patients represented ∼63% of the HIV-1–infected
population, this yields an estimate of 48% for ART-exposed
patients in the United States in 1998.
At the lower end of published estimates are the results from
Pillay et al. [21], who obtained a prevalence in the United
Kingdom of 17% in 2002 by dividing the number of patients
who had ever had a positive drug resistance test result by the
estimated number of treated patients in that year. Our approach
extends their analysis by further including clinical and virologic
information in the estimates, permitting an estimate of drug
resistance prevalence in the population without resistance tests
available.
Results from the analysis enclosing all participants seen since
1999 indicated an overall decrease of levels of drug resistance
in the Swiss HIV Cohort Study, at first glance contradicting
earlier predictions from mathematical models [12]. Yet those
apparent trends were most likely caused by the turnover of
high- and low-risk populations in the Swiss HIV Cohort Study.
When reanalyzed within a fixed sample of patients (our closed
cohort) or within groups of initial treatment, prevalence was
increasing over time as predicted by the models. Those yearly
increases were remarkably low, however. In their study from
2001, Blower et al. [11] considered a yearly rate of resistance
emergence of 10%—an optimistic scenario. With use of vi-
rologic failure as a proxy for resistance emergence, we estimated
rates of 4.7% (95% CI, 4.4%–5.1%) per 100 person-years of
receiving ART for patients who had initiated treatment with
cART and 2.1% (95% CI, 1.8%–2.4%) for those who had
started with potent cART ( , by log rank test) [13]. TheseP ! .001
lower rates most likely reflect the high standard of general
health care in Switzerland and the introduction of boosted PIs.
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Which of the estimation approaches presented herein may
be the most realistic? We believe that lower estimates from the
open cohort most closely resemble the situation of the HIV-
infected population in Switzerland and are thus most relevant,
because in patients without virologic failure or exposure to
mono- or dual-NRTI treatment, the upper estimate approach
makes a strong assumption of representativeness of individuals
with confirmed genotypic resistance. Of the 4295 study par-
ticipants who had never experienced virologic failure (i.e., the
low-risk and unknown groups), 306 patients (7.1%) had test
results that indicated the presence of resistance mutations. Of
these 306 patients, 181 (59.2%) had also undergone a resistance
test at baseline, and primary resistance mutations were detected
in 142 (78.5%) of these 181 tests. Thus, upper estimates were
disproportionately affected by primary drug resistance because
prevalence of transmitted resistance is estimated to be 10% for
Switzerland [26].
In turn, the lower method tended to underestimate preva-
lence, because pretreatment resistance testing has not been per-
formed uniformly in individuals from the low-risk and un-
known groups, although 64.5% of them had undergone at least
1 genotypic resistance test by 2007. Thus, assuming a primary
resistance prevalence of 10% for these 35.5% untested patients
yielded a new lower estimate of 40.7% for 2007, compared with
37.4% from the initial analysis, which suggests that the impact
of testing bias on lower estimates was minimal in our sample.
The Swiss HIV Cohort Study is highly representative of the
epidemic in Switzerland because it encompasses 49% of all
diagnosed HIV-infected individuals (http://www.shcs.ch).
Moreover, the Swiss HIV Cohort Study drug resistance database
contains all genotypic resistance tests performed in Switzerland,
making this one of the most comprehensive data sets on re-
sistance worldwide. An assessment of completeness of this da-
tabase revealed no systematic biases with regard to mode of
HIV acquisition or ethnicity (V.v.W., B.L., H.F.G.; unpublished
data). Thus, the open cohort approach should closely mirror
the dynamics not only in Switzerland but also in other countries
with a highly developed health care system. A potential limi-
tation for interpretation is the loss to follow-up rate, which
totalled 16% by the end of 2007. These patients were more
likely to have acquired HIV infection by injection drug use or
to originate from countries outside northwestern Europe (i.e.,
immigrants and asylum seekers)—populations that are known
to be harder to reach and that tend to have a higher attrition
from studies. In comparison to the closed cohort assessment,
prevalence estimates from the open cohort were ∼12% lower
in 2007, thus suggesting an impact of losses to follow-up on
our estimates. Most likely, the true bias is smaller than 12%,
because the population included in the closed cohort tended
to have a worse risk profile for virologic failures and, thus,
emergence of resistance in terms of treatment history and the
higher proportion of injection drug users (table 1).
To summarize, we conclude from our findings that HIV drug
resistance, although still a significant problem in highly treated
populations, appears to be moderating over time in highly de-
veloped health care systems with adequate resources. We spec-
ulate that resistance prevalence will further decrease at the pop-
ulation level because of the observed dilution effects, but also,
and more importantly, because durable therapy success can
more often be achieved with newer drugs and thus the emer-
gence of new drug resistance is considerably slowed. The sit-
uation in developing countries, where state-of-the-art diag-
nostic tools often are not routinely available and therapeutic
options are still limited, is likely to be different. In such settings,
the possibility of increasing drug resistance requires close
monitoring.
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